Tirzepatide (Zepbound) for the Treatment of Obesity

Valerie Coppenrath; Beth Mazyck

Aug 2024

Nirmatrelvir/Ritonavir Does Not Significantly Reduce Symptoms or Hospitalization in Vaccinated High-Risk Patients and Unvaccinated Patients

STEPS

New Drug Reviews

Tirzepatide (Zepbound) for the Treatment of Obesity

Valerie Coppenrath, PharmD

Beth Mazyck, MD

American Family Physician. 2024;110(2):199-200.

Author disclosure: No relevant financial relationships.

VALERIE COPPENRATH, PharmD, and BETH MAZYCK, MD, UMass Memorial HealthAlliance Fitchburg Family Practice, Fitchburg, Massachusetts

Address correspondence to Valerie Coppenrath, PharmD, at Valerie.coppenrath@mcphs.edu.

Author disclosure: No relevant financial relationships.

1.DailyMed. Drug label information. Zepbound—tirzepatide injection, solution. Updated March 28, 2024. Accessed July 22, 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
2.Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

This series is coordinated by Allen F. Shaughnessy, PharmD, assistant medical editor.

A collection of STEPS published in AFP is available at https://www.aafp.org/afp/steps.